trending Market Intelligence /marketintelligence/en/news-insights/trending/iQp_boN86lgbabu3RZ_Hxw2 content esgSubNav
In This List

Murad Chia Jei Biotechnology Q1 profit climbs 61.0% YOY

Blog

Investment Banking Essentials Newsletter: October Edition, Part - 2

Blog

Global M&A By the Numbers: Q3 2021

Blog

Capital Markets Activity Infographic: SPAC Volume Rises in Q3; Equity Issuance Drops but Remains Strong in Several Sectors

Blog

Insight Weekly: Global stock performance; hydrogen pilot projects; Powell's Fed future unsure


Murad Chia Jei Biotechnology Q1 profit climbs 61.0% YOY

Murad Chia Jei Biotechnology Co. Ltd. said its normalized net income for the first quarter amounted to 7 Taiwan cents per share, an increase of 48.6% from 5 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was NT$6.2 million, an increase of 61.0% from NT$3.8 million in the year-earlier period.

The normalized profit margin increased to 3.2% from 2.8% in the year-earlier period.

Total revenue climbed 41.1% on an annual basis to NT$196.1 million from NT$138.9 million, and total operating expenses rose 38.9% on an annual basis to NT$186.8 million from NT$134.5 million.

Reported net income rose on an annual basis to NT$11.0 million, or 12 cents per share, from NT$4.3 million, or 5 cents per share.

As of May 15, US$1 was equivalent to NT$30.44.